Citigroup Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $46.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target hoisted by research analysts at Citigroup from $38.00 to $46.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective indicates a potential upside of 67.46% from the stock’s previous close.

Several other equities analysts have also commented on AGIO. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. The Goldman Sachs Group lowered their price target on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a report on Thursday, November 20th. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Leerink Partners boosted their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus price target of $40.67.

Agios Pharmaceuticals Trading Down 0.8%

NASDAQ:AGIO opened at $27.47 on Thursday. The business’s 50-day moving average is $28.05 and its 200 day moving average is $33.26. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The company has a market capitalization of $1.61 billion, a P/E ratio of -3.86 and a beta of 0.89.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,872 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $27.02, for a total value of $77,601.44. Following the completion of the sale, the insider directly owned 34,793 shares of the company’s stock, valued at $940,106.86. The trade was a 7.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James William Burns sold 2,932 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the insider directly owned 31,718 shares in the company, valued at approximately $859,240.62. The trade was a 8.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,303 shares of company stock worth $901,977 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. Bellevue Group AG increased its position in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares in the last quarter. State Street Corp boosted its holdings in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares in the last quarter. Erste Asset Management GmbH grew its stake in shares of Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after acquiring an additional 40,000 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares in the last quarter. Finally, Commodore Capital LP increased its holdings in shares of Agios Pharmaceuticals by 0.6% during the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after acquiring an additional 13,287 shares in the last quarter.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Zacks Research raised multiple quarterly and full‑year EPS forecasts for AGIO across 2026–2028 (several Q1–Q4 and FY2026–FY2028 updates), reflecting expectations for smaller losses ahead — this is generally supportive for the stock. Zacks Research updates
• Positive Sentiment: Citigroup raised its price target to $46 and maintained a “buy” rating, implying material upside from current levels and providing a bullish broker signal for investors. Citigroup price target/coverage
• Neutral Sentiment: Short‑interest reports posted for early March show anomalous data (reported as 0 shares with NaN changes and a 0.0 days‑to‑cover), suggesting the published short data may be unreliable or not meaningful for trading signals right now.
• Negative Sentiment: Despite estimate upgrades, analysts still project sizable negative EPS (consensus ~($6.85) for the current full year), underlining that Agios remains loss‑making; persistent losses can constrain valuation and make the stock sensitive to execution or trial results.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.